reports
Public Storage: 1 director
A director at Public Storage maiden bought 2,149 shares at 278.960USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Barnwell Industries, Inc. Reports Results for its Second Quarter Ended...
Barnwell Industries, Inc. Reports Results for its Second Quarter Ended March 31, 2024 Production Increases for All Products Continued Reduction in General and Administrative Expenses HONOLULU, May 14, 2024 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) today reported financial results for its second fiscal quarter ended March 31, 2024. For the quarter, the Company had revenue of $5,774,000 and a net loss of $1,772,000, $0.18 per share. In the three months ended March 31, 2023, the Company reported quarterly revenue of $5,239,000 and a net loss of $1,237,000, $0.12 pe...
- Jonathan Moreland
SPWR SUNPOWER CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
FRAF FRANKLIN FINANCIAL SERVICES CO.
ZM ZOOM VIDEO COMMUNICATIONS
MRBK INC.
RYES MERIDIAN
LUMN PATRIOT MINEFINDERS INC.
VPV LUMEN TECHNOLOGIES INC.
MEGI INVESCO PA VALUE MUNI INC TST
IZEA MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
IZEA WORLDWIDE INC
- Jan Frederik Slijkerman
- Jeroen van den Broek
- Jesse Norcross
- Nadège Tillier
- Timothy Rahill
Coffee, Croissants & Credit/Aroundtown, Public Storage and WP Carey
Real Estate - Aroundtown shows successful result of GBP & USD Hybrid exchange and tender. Public Storage 1Q24: Slightly softer but no real concerns for credit investors. WP Carey 1Q24: Slight miss, but strong cash balance and liquidity
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
BRT BRT APARTMENTS
FPF FIRST TRUST INTERMEDIATE DURATION PREFERRED AND INCOME FUND
ZM ZOOM VIDEO COMMUNICATIONS
EGLE INC.
MPA EAGLE BULK SHIPPING
BUKS BLACKROCK MUNIYIELD PENNSYLVANIA FD
NPCT BUTLER NATIONAL CORP
ASGI NUVEEN CORE PLUS IMPACT FD
ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
- Jonathan Moreland
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
BRT BRT APARTMENTS
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
ZM ZOOM VIDEO COMMUNICATIONS
BFZ INC.
MPA BLACKROCK CALIF MUN INCOME TRUST
AMPX BLACKROCK MUNIYIELD PENNSYLVANIA FD
BIGZ AMPRIUS TECHNOLOGIES INC
ECAT BLACKROCK INNOVATION AND GROWTH TST
NPCT BLACKROCK ESG CAP ALLOCATION TR
ELVN NUVEEN CORE PLUS IMPACT FD
BMEZ IMARA INC
ASGI BLACKROCK HEALTH SCIENCES TERM TRUST
ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
- Jonathan Moreland
- Jonathan Moreland
CTRN CITI TRENDS INC.
CRMT AMERICA'S CAR-MART INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
CLSD CLEARSIDE BIOMEDICAL INC
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
ZM ZOOM VIDEO COMMUNICATIONS
DCTH INC.
HGBL DELCATH SYSTEMS
SPRB HERITAGE GLOBAL
LEE SPRUCE BIOSCIENCES INC
VPV LEE ENTERPRISES INC
INVESCO PA VALUE MUNI INC TST
Greenwich LifeSciences Extends Lock-up of Directors and Officers to Ju...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025 STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to June 30, 2025 which is approximately 57 months from date ...
- Jonathan Moreland
OPK OPKO HEALTH INC.
HOO HERBALIFE NUTRITION LTD.
CTRN CITI TRENDS INC.
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
QNBC QNB CORP.
ELAN ELANCO ANIMAL HEALTH INC.
ZM ZOOM VIDEO COMMUNICATIONS
KSM INC.
VTN DWS STRATEGIC MUNICIPAL INCOME TRUST
MPA INVESCO TRUST FOR INVESTMENT G
VPV BLACKROCK MUNIYIELD PENNSYLVANIA FD
LSXMK INVESCO PA VALUE MUNI INC TST
LIBERTY SIRIUSXM GROUP
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First ...
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research n...
- Jonathan Moreland
- Jonathan Moreland
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
AXR AMREP
ZM ZOOM VIDEO COMMUNICATIONS
KSM INC.
ETNB DWS STRATEGIC MUNICIPAL INCOME TRUST
ADPT 89BIO
SLRC ADAPTIVE BIOTECHNOLOGIES
WES SOLAR CAPITAL LTD.
VPV WESTERN MIDSTREAM PARTNERS LP
LSXMA INVESCO PA VALUE MUNI INC TST
LIBERTY SIRIUSXM GROUP
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved t...
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe. The Company's application to expand Flamingo-01 into Europe has been formally approved by Spain,...
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted b...
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators STAFFORD, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the expansion of the clinical trial into Europe. The Company's application to expand Flamingo-01 into Europe has been r...
Barnwell Industries, Inc. Announces Planned CEO Succession
Barnwell Industries, Inc. Announces Planned CEO Succession CEO Alexander Kinzler to Transition CEO Leadership to Barnwell of Canada President and COO Craig Hopkins Transition Aligned with Company’s New Focused Business Strategy HONOLULU, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Barnwell Industries, Inc. (NYSE American: BRN) ("Barnwell" or the "Company") is pleased to announce the CEO and President positions will transition from Alexander Kinzler to Craig Hopkins effective April 1, 2024. Mr. Kinzler has served as CEO of Barnwell since December 2016, having previously served in v...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.